Business Description
Avalo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05338F3064
Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.81 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -25.91 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -71.3 | |||||
| 3-Year EBITDA Growth Rate | 62.9 | |||||
| 3-Year EPS without NRI Growth Rate | 60.7 | |||||
| 3-Year FCF Growth Rate | 60.3 | |||||
| 3-Year Book Growth Rate | -21.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.31 | |||||
| 9-Day RSI | 45.26 | |||||
| 14-Day RSI | 50.62 | |||||
| 6-1 Month Momentum % | -83.6 | |||||
| 12-1 Month Momentum % | -99.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.82 | |||||
| Quick Ratio | 1.82 | |||||
| Cash Ratio | 1.61 | |||||
| Days Inventory | 5.61 | |||||
| Days Sales Outstanding | 7.21 | |||||
| Days Payable | 592.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 14.5 | |||||
| Shareholder Yield % | -254.47 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.25 | |||||
| Operating Margin % | -1217.82 | |||||
| Net Margin % | -1638.65 | |||||
| FCF Margin % | -1608.02 | |||||
| ROA % | -109.45 | |||||
| ROIC % | -98.59 | |||||
| ROC (Joel Greenblatt) % | -1270.36 | |||||
| ROCE % | -214.07 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.54 | |||||
| PB Ratio | 1.34 | |||||
| EV-to-EBIT | -0.23 | |||||
| EV-to-EBITDA | -0.24 | |||||
| EV-to-Revenue | 3.4 | |||||
| EV-to-Forward-Revenue | 0.3 | |||||
| EV-to-FCF | -0.19 | |||||
| Earnings Yield (Greenblatt) % | -438.87 | |||||
| FCF Yield % | -229.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.782 | ||
| EPS (TTM) (€) | -355.312 | ||
| Beta | 0 | ||
| Volatility % | 487.8 | ||
| 14-Day RSI | 50.62 | ||
| 14-Day ATR (€) | 1.320565 | ||
| 20-Day SMA (€) | 13.1605 | ||
| 12-1 Month Momentum % | -99.32 | ||
| 52-Week Range (€) | 0.0355 - 964.799992 | ||
| Shares Outstanding (Mil) | 1.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avalo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avalo Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avalo Therapeutics Inc Frequently Asked Questions
What is Avalo Therapeutics Inc(STU:C6K0)'s stock price today?
The current price of STU:C6K0 is €11.30. The 52 week high of STU:C6K0 is €964.80 and 52 week low is €0.04.
When is next earnings date of Avalo Therapeutics Inc(STU:C6K0)?
The next earnings date of Avalo Therapeutics Inc(STU:C6K0) is 2024-05-03 Est..
Does Avalo Therapeutics Inc(STU:C6K0) pay dividends? If so, how much?
Avalo Therapeutics Inc(STU:C6K0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers